BioSpace News Archive

Imagin Medical (CSE: IME) (OTCQB: IMEXF) (Frankfurt & Stuttgart Symbol: DPD2) (“Imagin” or the “Company”) is pleased to announce the launch of new social media campaigns via Twitter, Facebook and LinkedIn.

Natus Medical Incorporated announced that the Company signed a definitive agreement to transition its Peloton hearing screening services business to Pediatrix Medical Group After the completion of the transition, Pediatrix will manage all newborn hearing screening services for Peloton hospitals.

Discussion of UNITE platform as applied in cancer immunotherapy

Received initial $3 million payment in connection with amended AutoLap transaction

MellingMedical will offer Lumenis products to DoD Health Care patients

Peter S. Amenta, MD, PhD, announced that he will step down as President and CEO of Joslin Diabetes Center at the end of 2019. After that, he will remain an advisor to Joslin.

Final terms will be set out in a definitive agreement to be entered into by the parties.

Stealth BioTherapeutics (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced the presentation of new data from the open-label extension portion of the Phase 2/3 TAZPOWER study evaluating elamipretide in patients with Barth syndrome